Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 106, Issue 1-5, 2007, Pages 102-110

  Yue, Wei ^a   Fan, Ping ^a   Wang, Jiping ^a   Li, Yuebai ^a   Santen, Richard J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Breast cancer; c Src; EGFR; ER ; FTS; MAP kinase; mTOR; Tamoxifen

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTIESTROGEN; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FARNESYLTHIOSALICYLIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C SRC; PROTEIN INHIBITOR; RAPAMYCIN; RAS PROTEIN; RAS PROTEIN INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INDIVIDUALIZATION; LONG TERM CARE; PROTEIN PROTEIN INTERACTION; RECURRENT DISEASE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FARNESOL; GENOME, HUMAN; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN KINASES; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; SALICYLIC ACIDS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TAMOXIFEN; UP-REGULATION;

EID: 34548462552     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.05.008     Document Type: Article

References (38)

1. The ATAC Trialists' Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial, Lancet 359 (2002) 2131-2139.
2. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Therasse P., Palmer M.J., and Pater J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl. J. Med. 349 (2003) 1793-1802
3. Encarnacion C.A., Ciocca D.R., McGuire W.L., Clark G.M., Fuqua S.A.W., and Osborne C.K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26 (1993) 237-246
4. Brunner N., Frandesen T.L., Holst-Hansen C., Bei M., Thompson E.W., Wakeling A.E., Lippman M.E., and Clarke R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182.780. Cancer Res. 53 (1993) 3229-3232
5. Long B., McKibben B.M., Lynch M., and van den Berg H.W. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br. J. Cancer 65 (1992) 865-869
6. Nicholson R.I., and Gee J.M.W. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br. J. Cancer 82 (2000) 501-513
7. Joel P., Smith J., Sturgill T., Blenis J., and Lannigan D. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell. Biol. 18 (1998) 1978-1984
8. Gee J.M., Robertson J.F., Gutteridge E., Ellis I.O., Pinder S.E., Rubini M., and Nicholson R.I. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr. Relat. Cancer 12 (2005) S99-S111
9. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., and Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96 (2004) 926-935
10. Yue W., Wang J.-P., Conaway M.R., Li Y., and Santen R.J. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J. Steroid Biochem. Mol. Biol. 86 (2003) 265-274
11. Yue W., Wang J.-P., Li Y.-B., Fan P., and Santen R.J. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int. J. Cancer 117 (2005) 746-754
12. Alessi D.R., Kozlowski M.T., Weng Q.P., Morrice N., and Avruch J. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr. Biol. 8 (1998) 69-81
13. Pullen N., Dennis P.B., Andjelkovic M., Dufner A., Kozma S.C., Hemmings B.A., and Thomas G. Phosphorylation and activation of p70s6k by PDK1. Science 279 (1998) 707-710
14. Donovan C.H., Milic A., and Slingerland J.M. Constitutive MEK/MAPK activation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 276 (2001) 40888-40895
15. Gee J.M.W., Robertson J.F.R., Ellis I.O., and Nicholson R.I. Phosphorylation of ERK1/2 mitogen activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int. J. Cancer 95 (2001) 247-254
16. ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15 (1996) 1292-1300
17. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H., Mendelsohn M.E., and Shaul P.W. Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Inv. 103 (1999) 401-406
18. Endoh H., Sasaki H., Maruyama K., Takeyama K., Waga I., Shimizu T., Kato S., and Kawashima H. Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem. Biophys. Res. Commun. 235 (1997) 99-102
19. Watters J.J., Campbell J.S., Cunningham M.J., Krebs E.G., and Dorsa D.M. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcription. Endocrinology 138 (1997) 4030-4033
20. Razandi M., Pedram A., Park S.T., and Levin E.R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 278 (2003) 2701-2712
21. Song R.X., Barnes C.J., Zhang Z., Bao Y., Kumar R., and Santen R.J. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2076-2081
22. Song R.X.D., McPherson R.A., Adam L., Bao Y., Shupnik M., Kumar R., and Santen R.J. Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol. Endocrinol. 16 (2002) 116-127
23. Wong C.W., McNally C., Nickbarg E., Komm B.S., and Cheskis B.J. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 14783-14788
24. Masamura S., Santner S.J., Heitjan D.F., and Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 80 (1995) 2918-2925
25. Yue W., Wang J.-P., Conaway M., Masamura S., Li Y., and Santen R.J. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143 (2002) 3221-3229
26. McMahon L.P., Yue W., Santen R.J., and Lawrence J.C.J. Farnesylthiosalicylic acid inhibits mTOR activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol. Endocrinol. 19 (2005) 175-183
27. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signaling controls tumor cells growth. Nature 441 (2006) 424-430
28. Inoki K., Li Y., Zhu T., Wu J., and Guan K.-L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4 (2002) 648-657
29. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005) 179-193
30. Levin E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 19 (2005) 1951-1959
31. Fan P., Wang J.-P., Santen R.J., and Yue W. Long term treatment with tamoxifen facilitates translocation of ERα out of the nucleus and enhances its interaction with epidermal growth factor receptor in MCF-7 breast cancer cells. Cancer Res. 67 (2007) 1352-1360
32. Thomas S.M., and Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13 (1997) 513-609
33. Migliaccio A., Castoria G., Domenico D.I., De Falco A., Bilancio A., and Auricchio F. Src is an initial target of sex steroid hormone action. Ann. N. Y. Acad. Sci. 963 (2002) 185-190
34. Cato A.C., Nestl A., and Mink S. Rapid actions of steroid receptors in cellular signaling pathways. Sci. STKE 2002 (2002) RE9
35. Kim H., Laing M., and Muller W. c-Src-null mice exhibit defects in normal mammary gland development and ER signaling. Oncogene 24 (2005) 5629-5636
36. Feng W., Webb P., Nguyen P., Liu X., Li J., Karin M., and Kushner P.J. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol. Endocrinol. 15 (2001) 32-45
37. Shah Y.M., and Rowan B.G. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phorphorylation-dependent stabilization of estrogen receptor α promoter interaction and elevated steroid receptor coactivator 1 activity. Mol. Endocrinol. 19 (2005) 732-748
38. Planas-Silva M.D., Bruggeman R.D., Grenko R.T., and Smith J.S. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem. Biophys. Res. Commun. 341 (2006) 73-81